Shortcut to Registration
A small, short ‘add-on’ herpes zoster Phase I/II trial could pave the way for faster regulatory approval as described below.
In a severe herpes zoster ophthalmicus (HZO) infection, by complementing conventional acyclovir therapy with an add-on oral IBDV immunostimulatory treatment, it was demonstrated that the healing times could be reduced into a few days.
A picture is worth a thousand words
The CSO of HepC Inc’s HZO with orbital edema at the peak of disease and in recovery. The selfie pictures were taken between October 9, 2021, and October 12, 2021. Consent to the publication of patient information was granted by Tibor Bakacs, M.D., Ph.D., D.Sc., as he was the patient and the treating physician in this autobiography.